Immutep Ltd has released a press release.
Appendix 4E & 2022 Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1
- TACTI-002 2nd line lung cancer data presented at 2022 WCLC
- Quarterly Activities/Appendix 4C Cash Flow Report
- Immutep granted Japanese Patent for IMP761
- Webcast slides for 1st line NSCLC data from TACTI-002 trial
Later from Immutep
- New investigator-initiated ph2 trial in Soft Tissue Sarcoma
- Clinical Development Update for Eftilagimod Alpha
- Immutep Receives A$2.7 million R&D French Tax Incentive
- Fast Track granted by US FDA for Efti in 1st line NSCLC
- Abstracts accepted for Presentation at SITC 2022
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep